EXEO Capital Announces The Acquisition Of Chemical Process Technologies (CPT)
EXEO Capital Announces The Acquisition Of Chemical Process Technologies (CPT). EXEO Capital has announced that it has acquired a majority stake in chemical manufacturing Company Chemical Process Technologies (CPT).
CPT is currently the only manufacturer of animal active pharmaceutical ingredients (APIs) on the African continent. As is the case with human APIs, South Africa, in particular, is heavily reliant on imported animal APIs manufactured in countries like China and India. With CPT having made significant headway into the development of the larger pharma sector for both humans and animals, it is one of the few companies that is opening doors for South Africa as a manufacturer and exporter of APIs.
EXEO Capital partner, Herman Marais said in a statement, “The acquisition of CPT marks the first animal pharma investment by EXEO Capital. This strategic move into new commercial territory aligns with EXEO’s Agri-Vie Fund II mandate to invest in scalable businesses within the sub-Saharan agricultural and food value chains.” Chemical Process Technologies (CPT) is an innovative chemical synthesis company. The company prides itself in its capacity and ability to develop and commercialize competitive organic synthesis routes. The company synthesises several fine chemicals and formulates numerous end user products.
Dr Hannes Malan, CPT’s Chief Executive Officer said in a statement, “The fact that EXEO Capital management sees the same value in CPT that the current shareholders have identified highlights the opportunity that this growing industry presents. The transaction will allow for the accelerated implementation of projects to unlock this value and growth. We look forward to starting this next phase with EXEO Capital on board and the contributions they will make to this success story.”
